HeyJaredVandana Singh
- Indexed articles, last 90 days
- 173
- Latest publication
- Sep 16, 2026
- Outlet visibility, for benzinga.com
- Top 50K sites
- Earliest in this view
- Jul 5, 2026
Latest articles
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition (opens the original)
Read excerpt
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform. The all-stock deal hinges on shareholder approval and involves exchanging newly issued Xenetic shares for all outstanding Santersus equity. Following the transaction, the unified entity plans to rebrand as Santersus Bio, Inc. and trade on the Nasdaq Capital Market under the
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails (opens the original)
Read excerpt
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & Johnson (NYSE:JNJ) under a global license and develo
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029 (opens the original)
Read excerpt
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. The company validated its full-year 2026 financial guidance. Management anticipates adjusted earnings per share between $18.
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair (opens the original)
Read excerpt
Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash. The strategic acquisition integrates NerveTape, the first FDA-approved sutureless nerve repair device, into Axogen's existing surgical solutions for restoring peripheral nerve function. To finance the $200 million purchase price, Axogen launched an underwritten public offering of 4.91 million shares of common stock, priced at $42.50 per sha
Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary (opens the original)
Read excerpt
Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Kura said it is launching Caspian Therapeutics alongside a $50 million financing led by BVF Partners, with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Co. (NYSE:LLY), Kura Oncology, members of Kura's leadership team, and other investors. The stated goal is to advance the company's work in menin inhibition and expand development capacity around that
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For benzinga.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.